uploads/2017/11/LEP.png

How Pfizer’s Premarin and Other Legacy Established Products Performed

By

Updated

Premarin revenue trends

In 3Q17, Pfizer’s (PFE) Premarin generated revenues of $238 million, a ~2% decline on a YoY basis and a 3% decline on a quarter-over-quarter basis. In 3Q17, Premarin’s revenues from the US and international markets were $224 million and $14 million, respectively.

Pfizer’s Premarin family generated revenues of $711 million in the first nine months of 2017, a decline on a YoY basis. Lower sales volumes in certain emerging markets were primarily the reason behind declining revenues of Premarin in 3Q17 and in the first nine months of 2017. The price increases in the UK partially offset the decline of revenues in 3Q17. During both of these periods, foreign exchange had a favorable impact on international revenues.

Article continues below advertisement

Replax revenue trends

In 3Q17, Replax generated revenues of $50 million compared to $83 million in 3Q16. In 3Q17, Replax witnessed a ~17% decline on a quarter-over-quarter basis. In 3Q17, in the US market and international markets, Replax generated revenues of $26 million and $24 million, respectively. Replax’s competitors include GlaxoSmithKline’s (GSK) Imitrex and AstraZeneca’s (AZN) Zomig.

EpiPen revenue trends

In 3Q17, EpiPen reported revenues of $82 million, a ~25% decline on a YoY basis and a 9% decline on a quarter-over-quarter basis. In 3Q17, in the US and international markets, EpiPen generated revenues of $57 million and $26 million, respectively, compared to $91 million and $18 million in 3Q16.

Article continues below advertisement

Zithromax revenue trends

In 3Q17, Zithromax reported revenues of $61 million, a ~9% growth on a YoY basis and a 2% decline on a quarter-over-quarter basis. In 3Q17, Zithromax reported US and international market revenues of $3 million and $59 million, respectively.

Xalatan revenue trends

In 3Q17, Xalatan generated revenues of $83 million, which reflected a ~9% decline on a YoY basis and 2% growth on a quarter-over-quarter basis. In 3Q17, Xalatan reported revenues of $79 million from the international markets and $4 million in the US market.

Xalatan is used for the treatment of individuals with open-angle glaucoma or ocular hypertension. Xalatan’s competitors include Allergan’s (AGN) Lumigan, Novartis’s Travatan Z, and Merck’s Zioptan.

Article continues below advertisement

Zoloft revenue trends

In 3Q17, Zoloft generated revenues of $78 million, which is ~8% growth on a YoY basis and 13% growth on a quarter-over-quarter basis. In 3Q17, Zoloft reported revenues of $18 million and $59 million from the US and international markets.

Effexor revenue trends

In 3Q17, Effexor generated revenues of $78 million, ~8% growth on a YoY basis and 13% growth on a quarter-over-quarter basis. In 3Q17, Effexor reported revenues of $22 million and $54 million from the US and international markets, respectively.

Xanax revenue trends

In 3Q17, Xanax generated revenues of $58 million, ~5% growth on a YoY basis and 12% growth on a quarter-over-quarter basis. In 3Q17, in the US and international markets, Xanax reported revenues of $11 million and $46 million, respectively, compared to $12 million and $43 million in 3Q16.

The revenue growth of Pfizer’s legacy established products could boost the PowerShares Dynamic Pharmaceuticals Portfolio (PJP). Pfizer makes up about ~5.3% of PJP’s total portfolio holdings.

Advertisement

More From Market Realist